Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

Over time, clinicians have become increasingly comfortable embracing the prescription of biosimilars—highly similar versions of innovator or reference biological agents—for their patients with inflammatory diseases. Although a switch from a reference product to a licensed biosimilar version (or vice...

Descripción completa

Detalles Bibliográficos
Autores principales: Mysler, Eduardo, Azevedo, Valderilio Feijó, Danese, Silvio, Alvarez, Daniel, Iikuni, Noriko, Ingram, Beverly, Mueller, Markus, Peyrin-Biroulet, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578069/
https://www.ncbi.nlm.nih.gov/pubmed/34705255
http://dx.doi.org/10.1007/s40265-021-01610-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578069/
https://www.ncbi.nlm.nih.gov/pubmed/34705255
http://dx.doi.org/10.1007/s40265-021-01610-1

Ejemplares similares